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Finally More Light Than Heat*Robert A. Vogel, MDSEE PAGE 910I cannot remember practice guidelines moredelayed, groundbreaking, and controversialthan the 2013 American College of Cardiology/
American Heart Association cholesterol guidelines
(1). They are groundbreaking for using a new race-
speciﬁc estimator to generate both 10-year and life-
time cardiovascular risk, for considering both stroke
and coronary heart disease risk, and especially for
replacing low-density lipoprotein (LDL) cholesterol
goals with speciﬁc drug and dose treatment targets.
Changes to our practice guidelines were badly
needed, because the concept of “getting to goals”
was never evidence based and because three-
quarters of younger patients with myocardial infarc-
tions would not have qualiﬁed for cholesterol
treatment under the old guidelines just before their
ﬁrst events (2). The new guidelines have ignited a
ﬁrestorm of dissent, ranging from perceived author
conﬂict of interest to overestimation of risk to thera-
peutic nihilism regarding the beneﬁts of statin treat-
ment (3,4). Most of this criticism badly misses the
mark, but how many and which patients should be
considered for statin therapy are valid points for
discussion.
First, what percent of a middle-aged population
should be on statin therapy? This number is not
difﬁcult to estimate. I would recommend lifestyle
modiﬁcations and statins to patients who already
have had or I deﬁnitively know will experience
atherosclerotic cardiovascular events in the future.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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11570).Assuming attainment of age 40 years, symptomatic
coronary heart disease occurs in 49% of men and 32%
of women over their lifetimes (5). Additionally,
stroke, most of which is atherothrombotic, occurs in
16% of men and 21% of women age 55 to 75 years (6).
Accounting for stroke plus heart disease overlap,
ideally 61% of men and 48% of women age 40 to 75
years should be considered for statin therapy.
Because we cannot deﬁnitively identify those who
will have future events, treating an even larger
percent of the population may be reasonable. Starting
statins earlier than age 40 also may be reasonable,
because Mendelian analysis suggests that earlier LDL
cholesterol lowering is more beneﬁcial (7). Taken
from this point of view, the new guidelines’ esti-
mated increase in recommended statin use from 38%
to 49% of the middle-aged American population (8)
should be recognized as strong support for the up-
date rather than as criticism.The second valid point for discussion is whether
the new guidelines correctly identify the speciﬁc
patients who will beneﬁt from statin therapy, namely,
those who will experience future cardiovascular
events. In this issue of the Journal, Johnson and
Dowe (9) compare recommended statin use according
to the 2001 and 2013 guidelines for patients with and
without demonstrated coronary artery disease. In this
single-center, retrospective study, they assessed
coronary atherosclerosis burden by computed tomo-
graphic angiography in 3,076 subjects referred for
angiography, using 3 scoring techniques. Unavailable
pre-statin treatment values for total and low-density
lipoprotein cholesterol were estimated from on-
treatment data using assumed statin efﬁcacy. Under
the 2001 guidelines, 59% of patients with $50% ste-
nosis of the left main coronary artery and 40% of
patients with $50% stenosis of other branches would
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921not have been treated. The comparable results for the
2013 guidelines were 19% and 10%. The use of LDL
cholesterol targets seriously degraded the accuracy of
the 2001 guidelines for statin assignment. The pro-
portion of patients assigned to statin therapy was 15%
higher under the new guidelines, which translates to
8.9 million more Americans on statin treatment. The
study concludes that the new guidelines match statin
assignment to patients’ total plaque burden better
than the older guidelines, with only a modest in-
crease in the number of patients assigned to statin
therapy.
This study is important because it strongly sup-
ports prior ﬁndings (2) that the 2001 guidelines
undertreated especially younger, high-risk patients.
The major reason for the undertreatment with the
2001 guidelines resulted from their use of LDL
cholesterol goals. The new guidelines appear to
reduce this critical limitation. At the same time, by all
3 plaque assessment techniques, the new guidelines
recommended statin therapy to fewer subjects
without demonstrable disease than did the old
guidelines. In short, the present study suggests that
the new guidelines are a major clinical and concep-
tual improvement over the older ones.
Limitations of this study deserve comment,
although none totally discount its seminal ﬁndings.
The select cohort studied was referred for angiog-
raphy predominately for nonspeciﬁc symptoms,
indeterminate stress test results, or the presence of
multiple risk factors and therefore was at higher than
average risk. Although not representative of a true
population cross section, only 20% of the men and
13% of the women had known coronary artery disease
before angiography. Still, two-thirds of the cohort
studied had coronary artery disease. Total and LDL
cholesterol baseline values were estimated but notmeasured in the majority of subjects who were
already on statin treatment. The variability of re-
sponses and adherence to therapy limit accurately
knowing whether either set of guidelines would
recommend treatment. As such, it raises the question
of whether we should have a risk estimator that takes
into account patients already on statins, as we do for
those already on antihypertensive treatment. The
study’s most important and inescapable limitation is
that plaque burden is a good but imperfect predictor
of future coronary events. Coronary artery disease is
not the same as coronary heart disease, for which we
have considerable prospective data on statin efﬁcacy.
Plaque density and other local and systemic markers
of plaque vulnerability were not measured. The new
guidelines advocate the use of coronary calcium
scoring and other measures to clarify intermediate
risk. Whether coronary calcium and/or angiography
should be routinely used in determining the need for
statin therapy is a complex, contentious issue that
will require prospective evaluation.
Finally, the present study asks the fundamental
question of whether guidelines are really distilled
wisdom or simply working hypotheses. In a regula-
tory world in which the quality of medical care,
and hence reimbursement, is evaluated by adherence
to treatment guidelines, do guidelines need to be
prospectively validated? Do we need fewer com-
ments from experts and medical societies and more
science? I would argue the latter. So does the present
study.
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